1-15 of 15
Patrick R. Hagner, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Patrick R. Hagner, PhD, Hsiling Chiu, MS, Vivek S. Chopra, PhD, Martino S. Colombo, PhD, Nisha Patel, PhD, Maria Ortiz, Remco S. Loos, PhD, Fadi Towfic, PhD, Michelle Waldman, MS, Anita K Gandhi
Journal: Blood
Blood (2019) 134 (Supplement_1): 306.
https://doi.org/10.1182/blood-2019-126681
Published: 2019
Journal Articles

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

C. Chris Huang, PhD, Yumi Nakayama, PhD, Matthew Stokes, PhD, Fadi Towfic, PhD, chung-Wein Lee, Yan Ren, Mathieu Marella, PhD, Maria Wang, Patrick R. Hagner, PhD, Suzana Couto, Kathryn Newhall, Anita K Gandhi
Journal: Blood
Blood (2019) 134 (Supplement_1): 2797.
https://doi.org/10.1182/blood-2019-123691
Published: 2019
Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi
Journal: Blood
Blood (2019) 134 (Supplement_1): 1580.
https://doi.org/10.1182/blood-2019-126115
Published: 2019
Journal Articles

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Kerstin Wenzl, PhD, Maria Ortiz, Nicholas Stong, PhD, C. Chris Huang, PhD, Matthew J. Maurer, MS, Fadi Towfic, PhD, Patrick R. Hagner, PhD, Hamid Nikbakht, PhD, Matthew Stokes, PhD, Sneh Lata, PhD, Sitharthan Kamalakaran, PhD, Konstantinos Mavrommatis, PhD, Matthew Trotter, PhD, Rebecca L. King, MD, Brian K. Link, MD, Susan L. Slager, PhD, Yan Asmann, PhD, Myron Czuczman, Stephen M Ansell, MD PhD, Thomas M. Habermann, MD, James R. Cerhan, MD PhD, Grzegorz Nowakowski, MD, Anne J Novak, PhD, Anita K Gandhi
Journal: Blood
Blood (2019) 134 (Supplement_1): 919.
https://doi.org/10.1182/blood-2019-123694
Published: 2019
Journal Articles

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Maria Ortiz, Kerstin Wenzl, PhD, Matthew Stokes, PhD, C. Chris Huang, PhD, Matthew J. Maurer, MS, Fadi Towfic, PhD, Patrick R. Hagner, PhD, Alexander Ratushny, PhD, Mark McConnell, PhD, Samuel A Danziger, PhD, Nicholas Stong, PhD, Sneh Lata, PhD, Sitharthan Kamalakaran, PhD, Konstantimos Mavrommatis, PhD, Matthew Trotter, PhD, Rebecca L. King, MD, Brian K. Link, MD, Susan L. Slager, PhD, Yan Asmann, PhD, Myron Czuczman, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Anita K Gandhi, Anne J Novak, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 923.
https://doi.org/10.1182/blood-2019-122756
Published: 2019
Journal Articles

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Yumi Nakayama, PhD, Matthew E. Stokes, PhD, Michelle Waldman, MS, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4133.
https://doi.org/10.1182/blood-2018-99-114469
Published: 2018
Journal Articles

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Patrick R. Hagner, PhD, Fadi Towfic, PhD, Frank Schmitz, MD PhD, Xuehai Wang, PhD, Andrew P. Weng, MD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4211.
https://doi.org/10.1182/blood-2018-99-114481
Published: 2018
Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 237.
https://doi.org/10.1182/blood-2018-99-111605
Published: 2018
Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5622.
https://doi.org/10.1182/blood-2018-99-118885
Published: 2018
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

Cecilia Carpio, MD, Reda Bouabdallah, MD, Loic Ysebaert, MD PhD, Juan-Manuel Sancho, MD PhD, Gilles Salles, MD PhD, Raul Cordoba, MD PhD, Antonio Pinto, MD, Mecide Gharibo, MD, Drew W. Rasco, MD, Carlos Panizo, MD PhD, Jose A. Lopez-Martin, MD PhD, Armando Santoro, MD, Antonio Salar, MD PhD, Silvia Damian, MD, Alejandro Martín, MD PhD, Gregor Verhoef, MD PhD, Xin Wei, Patrick R. Hagner, PhD, Kristen Hege, MD, Alberto Risueño, PhD, Anita K. Gandhi, PhD, Tonia J. Buchholz, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4118.
https://doi.org/10.1182/blood.V130.Suppl_1.4118.4118
Published: 2017
Journal Articles

Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Alberto Risueño, PhD, Patrick R. Hagner, PhD, Celia Fontanillo, PhD, Amira Djebbari, DSc, Joel S. Parker, PhD, Clifton P. Drew, PhD, Fadi Towfic, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Matthew Trotter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2830.
https://doi.org/10.1182/blood.V130.Suppl_1.2830.2830
Published: 2017
Journal Articles

Combination of Lenalidomide and Rituximab (R 2 ) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy

Hsiling Chiu, Patrick R. Hagner, PhD, Preeti Trisal, Michelle Waldman, Chloe Cavanaugh, Anita K. Gandhi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1531.
https://doi.org/10.1182/blood.V130.Suppl_1.1531.1531
Published: 2017
Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Julio C. Chavez, MD, Umberto Vitolo, MD, Jason B. Kaplan, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Loretta Nastoupil, MD, Philippe A. Cassier, MD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Ranjana H. Advani, MD, Iris Isufi, MD, Thomas E Witzig, MD, Michael Petrarca, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1551.
https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551
Published: 2017
Journal Articles

Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs ® Immunomodulatory Compounds

Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Patrick R Hagner, PhD, Anita K. Gandhi, PhD, Maria Wang, PhD, Michael D Amatangelo, PhD, Ling Lu, BS, Huisheng Wang, MS, Mike Breider, DVM, PhD DACVP, Yan Ren, MS, Antonia Lopez-Girona, PhD, Anjan Thakurta, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4700.
https://doi.org/10.1182/blood.V124.21.4700.4700
Published: 2014